WWFHTX is a grassroots initiative that unites health consumers, biopharmaceutical company employees vendors, suppliers, academic and community partners.
The prescription drug supply chain, including #PBMs, is now making more money off of those #medicines than the #biopharma companies that developed them. https://t.co/rOP8XYNOvY @txhbi From: Berkeley Research Group #BRG
“What was meant to be a patient-focused program is now a hospital markup program where large, tax-exempt hospital systems buy discounted drugs, mark them up by as much as 1,000% or more and bill patients and insurers the list price.” #340B#340BReform https://t.co/c21Fu4MjMM
.@wendellpotter testifies to TX lawmakers: “. . . something is deeply broken when [#healthinsurance] coverage keeps getting more expensive while care becomes harder to access. . .” @txhbi https://t.co/6ntNaEehKh
Per @sallypipes of @PacificResearch, with so little federal oversight, some hospitals are using the #340B program as an unchecked profit stream. @txhbi https://t.co/tB4FjEVLki
Three in four surveyed adults are concerned hospitals benefiting from #340B drug discounts pursue aggressive debt collection practices against patients. #340BReform@TXDisabilities https://t.co/yWJvjULyXM
Per @AdapAdvocacy, #340B has become a cash cow for its providers, with many large hospital systems abusing this program, costing patients. #340BReform@txhbi https://t.co/9CTvRoTB7y
A lack of transparency in the #340B program provides fertile ground for waste, fraud and abuse. #340BReform is needed. @IAFAccess https://t.co/iiBovvA4Hp
The practices of both middlemen #PBMs and #healthinsurance companies directly contribute to the high out-of-pocket costs patients are forced to pay. https://t.co/4qxsyfrh1H
Dr. Robert Popovian of @GHLForg on #340BReform: “Hospitals taking in hundreds of millions of dollars, if not billions, in #340B-related revenue, should have to show how that money is actually helping patients.” @TCCRI https://t.co/GlkmfA2DUR
Learn more about the Lone Star State’s continued growth and leadership in #biopharma R&D, growth and innovation. #Texas@BioNorthTX https://t.co/Elz3R1MOtc
How #pricecontrols on drugs reduce the incentive to invest in risky research, resulting in fewer new drugs, fewer cures and fewer lives saved. @txhbi https://t.co/k6r5B1fZNr
Read how #healthinsurance companies have raised premiums, cut benefits, narrowed provider networks & shed members deemed too costly to cover – all at the expense of patients. #EndInsuranceAbuse@Stopafib https://t.co/lDKhCdIauX
“As it stands currently, model estimates issued by the White House on cost savings from #MFN prices are highly speculative and depend on a set of unrealistic assumptions.” #MostFavoredNation@NTxCommission https://t.co/85o7Lml2uE
.@ASCO issues new policy statement/recommendations for needed #340BReform measures to address accountability in the #340B program. @IAFaccess https://t.co/xPqiYMYuYn
Policies intended to accelerate access can undermine innovation if they weaken the intellectual property systems that sustain drug development in the first place. Henry Hadad of @bmsnews examines how recent EU IP reforms could reshape investment decisions and ultimately limit patient access to future therapies: https://t.co/tWZJM44wN0
New Jersey is home to one of the world's leading life sciences hubs – supporting hundreds of thousands of jobs and fueling billions in economic activity. MFN pricing puts this all at risk and would limit patient access to medicines, reduce R&D investment, and slow the next generation of cures.
More from WWFH’s @DLeonard_DC and @ChrissyButeas of @HINJ_ORG: https://t.co/DKYg96YeXP